# Monte Rosa Therapeutics

Source: https://onco.cc/companies/monte-rosa/  
OnCo record `monte-rosa` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Molecular-glue degrader company with a GSPT1 degrader in phase 2 for AR-mutant prostate cancer and a CCNE1-directed glue in preclinical development.

## Summary

MRT-2359 (GSPT1) first patient dosed in phase 2 MODeFIRe-1 with apalutamide in AR-mutation-positive mCRPC (August 2026). AACR 2026: CCNE1-directed glue degrader produced regressions in CCNE1-amplified ovarian, breast, and gastric models with better selectivity than CDK2 inhibitors. QuEEN discovery engine; Novartis and Roche partnerships.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Boston, MA
- Type: biotech
- Website: https://www.monterosatx.com
- Ticker: GLUE

## Sources

- MODeFIRe-1 first patient: https://www.globenewswire.com/news-release/2026/08/24/3349601/0/en/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt-2359-in-combination-with-apalutamide-in-patients-with-ar-mutation-positive-metastatic-cas.html

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [Cancer Research Horizons](https://onco.cc/companies/cancer-research-horizons/), [Novartis](https://onco.cc/companies/novartis/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [Study of Oral MRT-2359 in Selected Cancer Patients](https://onco.cc/trials/nct05546268/), [Study of Oral MRT-2359 With Apalutamide in Prostate Cancer](https://onco.cc/trials/nct07745361/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- ideas: [An open degrader consortium against every undruggable driver transcription factor](https://onco.cc/ideas/idea-moon-open-degrader-consortium/), [Design protein degraders small enough to get into the brain](https://onco.cc/ideas/idea-bio2-brain-penetrant-glue-degraders/), [Molecular glues that break the MYC-MAX partnership](https://onco.cc/ideas/idea-bio1-myc-max-molecular-glue/), [Screen glue-like compounds against every cancer cell line and publish it](https://onco.cc/ideas/idea-bio1-glue-degrader-atlas/)

---
JSON: https://onco.cc/api/v1/entities/monte-rosa.json